Camurus AB CAMX
OMXSTO · Sweden · Health Technology
SEK 623.50-1.00 (-0.16%)
Market closed· · SEK · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · SEK · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Camurus (NASDAQ STO: CAMX) today announced that the US Food and Drug Administration (FDA) has accepted for review the resubmission of the New Drug Application (NDA) for CAM2029, octreotide extended-release injection, for the treatment of patients with acromegaly. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of 18 December 2026.
Camurus AB (CAMRF) reports robust revenue growth and record product sales, while navigating regulatory hurdles and increased operational costs.
Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) is one of the 10 best mid-cap stocks that could double your money. Based on consensus estimates, as of June 12, the stock offers more than 159% upside potential at the current level. On June 11, Leerink analyst Joseph Schwartz maintained an Outperform rating on Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) following a […]
Camurus (NASDAQ STO: CAMX) today announced that Eli Lilly and Company ("Lilly") has exercised its option to include amylin receptor agonists (amylin) in the collaboration and license agreement entered in June 2025. The decision extends Lilly's exclusive, global rights to Camurus' FluidCrystal® technology for the development and commercialization of long acting cardiometabolic drug medicines to an additional compound class.
Camurus (OM:CAMX) drew fresh attention after recent share price moves, with the stock up slightly over the past week but down year to date. This has prompted investors to reassess its current valuation. See our latest analysis for Camurus. Camurus’s recent share price return has been mixed, with a 1-day gain of 1.06% and a 90-day share price return of 4.67%. However, the stock remains down 13.97% year to date, while the 5-year total shareholder return of 154.96% reflects much stronger...
[220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global Bioprocess Automation Software Market size & share revenue was valued at approximately USD 1.67 Billion in 2025 and is expected to reach USD 1.90 Billion in 2026 and is expected to reach around USD 6.19 Billion by 2035, at a CAGR of 14 between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are Xeris Pharmaceuticals
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.